|1.||García Vicente, A: 1 article (09/2002)|
|2.||González, R: 1 article (09/2002)|
|3.||Poblete García, V M: 1 article (09/2002)|
|4.||Rodado Marina, S: 1 article (09/2002)|
|5.||Soriano Castrejón, A: 1 article (09/2002)|
|2.||Colorectal Neoplasms (Colorectal Cancer)
03/01/1994 - "Sixteen patients with completely resected, CEA-producing colorectal cancer were given 1 mg of 99mTc-labeled IMMU-4 intravenously with no toxic side effects. "
10/01/1993 - "Immu-4 scintigraphy is a safe and convenient diagnostic approach to colorectal cancer. "
10/01/1993 - "Immunoscintigraphy with Immu-4 correctly detected 28 primary colorectal cancers of 29 and 12 of 12 recurrent colorectal cancers. "
09/01/2002 - "To assess the utility of nuclear imaging with labelled monoclonal antibody against CEA immu-4 Fab' (CEA-scan) and the computed tomography (CT) in the follow-up of colorectal cancer after therapy and his accuracy in the detection of recurrent disease. "
12/01/1995 - "A total of 127 patients with metastatic colorectal cancer were examined [IgG1, BW 431/26 (Behringwerke, Marburg, Germany) n = 50; F(ab')2, F023C5 (Sorin Biomedica, Saluggia, Italy) n = 58; Fab', IMMU-4 (Immunomedics, Morris Plains, NJ) n = 19]. "
03/01/1994 - "These results suggest that 99mTc IMMU-4 scintigraphy is an important addition to the armamentarium available for diagnostic imaging and may help detect occult metastatic cancer missed by abdominal and pelvic CT in patients with rising CEA levels."
12/01/1995 - "A larger opportunity awaits other preparations reported at this conference, especially 99mTc-labeled Immu-4 carcinoembryonic antigen, which is significantly better than CT for determining resectability of recurrent cancer (T. "
06/15/1993 - "Four (31%) of 13 patients undergoing exploration and imaged with ZCE-025 and 5 (36%) of 14 imaged with IMMU-4 had complete tumor resection. "
|4.||Neoplasm Metastasis (Metastasis)
11/01/1992 - "A blinded prospective study of 34 patients with colorectal adenocarcinoma using the Fab' fragment of the anticarcinoembryonic antigen monoclonal antibody type IMMU-4 labeled with technetium 99m was conducted to compare, on a lesion-by-lesion basis, the findings of radioimmunoscintigraphy, preoperative computed tomography, and exploratory celiotomy. "
|2.||Technetium (Technetium 99m)
|3.||Immunoglobulin Fab Fragments
|4.||Immunoglobulin G (IgG)
|6.||technetium Tc 99m arcitumomab
|7.||monoclonal antibody ZCE 025